Talecris Launches $1 Million Program To Support Research Projects
Posted May 4, 2006
RESEARCH TRIANGLE PARK, N.C. — Talecris Biotherapeutics, the billion-dollar biotech firm created in 2005 with the acquisition of Bayer Biological Projects, is launching an annual $1 million research plan to encourage studies of immunoglobulin (IGIV) therapies.
The company said the funds would be used to support science and clinical research projects in immunology, hematology and neurology. It is calling the program
Talents (Talecris New Trials Support Program)
Talecris manufacturers Gamunex, an IGIV therapy designed to boost the body's immune system.
"Talecris Biotherapeutics is committed to advancing standards of care involving biotherapeutic products such as IGIV," said Alberto Martinez, chief executive officer of Talecris. "Through the Talents program, we will support the intellectual endeavors of the IGIV research community in a way that complements our own innovative in-house research. Together, we expect to add significantly to the scientific body of knowledge about disease mechanisms effectively treated by IGIV and, ultimately, to improve patient care."
Gamunex contains antibodies purified from the donated blood plasma and is used to treat a variety of problems, both as a means of immune replacement and for modulating the immune system, according to the company.
Talecris reported $1 billion in revenues in 2005 and employs some 1,800 people.